IL266486A - Pharmaceutical preparations and methods for cancer treatment - Google Patents
Pharmaceutical preparations and methods for cancer treatmentInfo
- Publication number
- IL266486A IL266486A IL266486A IL26648619A IL266486A IL 266486 A IL266486 A IL 266486A IL 266486 A IL266486 A IL 266486A IL 26648619 A IL26648619 A IL 26648619A IL 266486 A IL266486 A IL 266486A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treatment
- methods
- pharmaceutical compositions
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/351,966 US10272068B2 (en) | 2012-01-17 | 2016-11-15 | Pharmaceutical compositions and methods |
| PCT/US2017/061682 WO2018093820A1 (en) | 2016-11-15 | 2017-11-15 | Pharmaceutical compositions and methods for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL266486A true IL266486A (en) | 2019-07-31 |
Family
ID=60570232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266486A IL266486A (en) | 2016-11-15 | 2019-05-06 | Pharmaceutical preparations and methods for cancer treatment |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3541411A1 (ko) |
| JP (2) | JP2019537608A (ko) |
| KR (2) | KR20230003314A (ko) |
| CN (1) | CN110167580A (ko) |
| AU (1) | AU2017361080A1 (ko) |
| BR (1) | BR112019009799A2 (ko) |
| CA (1) | CA3040922A1 (ko) |
| EA (1) | EA201991192A1 (ko) |
| IL (1) | IL266486A (ko) |
| MX (1) | MX2019005450A (ko) |
| PH (1) | PH12019500758A1 (ko) |
| WO (1) | WO2018093820A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021022784A2 (pt) | 2019-05-14 | 2022-03-22 | Tyme Inc | Composições e métodos para tratamento do câncer |
| EP4045027A1 (en) * | 2019-10-15 | 2022-08-24 | Tyme, Inc. | Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer |
| CN115515575A (zh) * | 2020-01-17 | 2022-12-23 | 迪美公司 | 用于调节癌症的酪氨酸衍生物 |
| CN111358777A (zh) * | 2020-02-24 | 2020-07-03 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种提高外周血单个核细胞线粒体功能的方法和应用 |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225435A (en) | 1990-05-18 | 1993-07-06 | Yale University | Soluble melanin |
| WO2006036892A2 (en) * | 2004-09-24 | 2006-04-06 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| WO2006032299A1 (en) * | 2004-09-24 | 2006-03-30 | Susanna Miettinen | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| US8481498B1 (en) * | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
| US20130183263A1 (en) * | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
| NZ628757A (en) * | 2012-01-17 | 2016-07-29 | Tyme Inc | Pharmaceutical compositions and methods for treating cancer |
| US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
-
2017
- 2017-11-15 EP EP17808688.0A patent/EP3541411A1/en not_active Withdrawn
- 2017-11-15 EA EA201991192A patent/EA201991192A1/ru unknown
- 2017-11-15 WO PCT/US2017/061682 patent/WO2018093820A1/en unknown
- 2017-11-15 KR KR1020227043322A patent/KR20230003314A/ko not_active Application Discontinuation
- 2017-11-15 MX MX2019005450A patent/MX2019005450A/es unknown
- 2017-11-15 CA CA3040922A patent/CA3040922A1/en active Pending
- 2017-11-15 KR KR1020197016782A patent/KR20190084291A/ko not_active Application Discontinuation
- 2017-11-15 BR BR112019009799A patent/BR112019009799A2/pt unknown
- 2017-11-15 CN CN201780070447.8A patent/CN110167580A/zh active Pending
- 2017-11-15 AU AU2017361080A patent/AU2017361080A1/en active Pending
- 2017-11-15 JP JP2019524973A patent/JP2019537608A/ja active Pending
-
2019
- 2019-04-08 PH PH12019500758A patent/PH12019500758A1/en unknown
- 2019-05-06 IL IL266486A patent/IL266486A/en unknown
-
2022
- 2022-11-18 JP JP2022184577A patent/JP2023018029A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN110167580A (zh) | 2019-08-23 |
| JP2023018029A (ja) | 2023-02-07 |
| JP2019537608A (ja) | 2019-12-26 |
| MX2019005450A (es) | 2019-07-04 |
| EA201991192A1 (ru) | 2019-10-31 |
| KR20230003314A (ko) | 2023-01-05 |
| KR20190084291A (ko) | 2019-07-16 |
| BR112019009799A2 (pt) | 2019-08-06 |
| EP3541411A1 (en) | 2019-09-25 |
| PH12019500758A1 (en) | 2019-07-24 |
| WO2018093820A1 (en) | 2018-05-24 |
| CA3040922A1 (en) | 2018-05-24 |
| AU2017361080A1 (en) | 2019-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258955A (en) | Preparations and methods for the treatment of cancer | |
| EP3490581A4 (en) | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR TREATMENT OF CANCER | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1247630A1 (zh) | 用於增强癌症治療的效果的組合物和方法 | |
| IL268814A (en) | Preparations and methods for the treatment of cancer | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| HK1247931A1 (zh) | 用於診斷和治療癌症的組合物和方法 | |
| IL258854A (en) | Preparations containing cannabidiol and secondary medicinal agents for cancer treatment | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| EP3353204A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| IL263793A (en) | Compounds and preparations for the treatment of cancer | |
| IL261278A (en) | Pharmaceutical compositions for the treatment of cancer | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
| IL265824A (en) | Methods and pharmaceutical compositions for the treatment of kidney cancer | |
| IL255169A0 (en) | Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| IL272147A (en) | Methods and preparations for the treatment of cancer | |
| PL3290051T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| EP3681498A4 (en) | PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT | |
| EP3515431A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
| IL257689A (en) | Pharmacological preparations and methods for the treatment of diseases associated with hypoxia | |
| EP3563856A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND USE THEREOF | |
| IL255168A0 (en) | Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer |